… Our findings regarding ctDNA as a biomarker for immune checkpoint blockade response
are similar to other proof-of-concept studies in the literature on ctDNA and systemic therapies. …

… such as CTLA-4 and PD-1/PD-L1 can be challenging, as tumors may seem to enlarge or …
tumor DNA (ctDNA) levels could serve as an early indicator of true changes in tumor burden …

… from patients subjected to immune checkpoint blockade therapy, we prospectively …
checkpoint blockade therapy. Quantitative PCR showed time-dependent dynamic changes in DNA …

… tumor DNA (ctDNA) detection by targeted deep sequencing in patients with metastatic renal
cell carcinoma (mRCC) treated with immune checkpoint blockades (… in primary tumors and …

… tumor DNA (ctDNA) and T-cell expansion can be used to assess responses to immune
checkpoint blockade … measured by pathologic assessment of residual tumor after anti-PD1 therapy…

… tumor-associated neoantigens carry information about drug sensitivity and resistance to
the immune checkpoint blockade … difficult to track neoantigens by circulating tumor DNA (ctDNA) …

… Gene expression analyses of clinical tumor samples have found that checkpoint
blockade response correlates with T cell infiltration, cytotoxic function, antigen processing, …

… solid tumors, and describe modes of immune response failure and the physiologic role of
immune checkpoints. We also review the known mechanisms of immune checkpoint inhibitors, …

… Prior to the shift in the clinical research landscape brought about by the success of immune
checkpoint blockade (ICB) in multiple tumor types, chemotherapy, radiation, surgery, and …

… , tumor mutational burden (TMB), and high microsatellite instability are potentially applicable
to predict the efficacy of immune checkpoint blockade (… in the DNA damage response (DDR) …